CIK 0001395937
- Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 320162505
- Phone
- +1 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- 4 Grant or award Director acquired 25,000 shares (grant or award)
- 4 Grant or award Director acquired 25,000 shares (grant or award)
- 4 Grant or award Director acquired 25,000 shares (grant or award)
- 4 Grant or award Director acquired 25,000 shares (grant or award)
- 4 Open-market buy Chief Financial Officer bought 1,250 shares at $20.03 ($25,037)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Chief Executive Officer acquired 146,250 shares (grant or award)
- 4 Other acquisition Chief Financial Officer acquired 2,045 shares (other)
- 4 Grant or award President, Head of R&D acquired 47,813 shares (grant or award)
- 4 Grant or award Director acquired 17,000 shares (grant or award)
- 4 Grant or award Director acquired 17,000 shares (grant or award)
- 4 Grant or award Director acquired 17,000 shares (grant or award)
- 4 Grant or award Director acquired 17,000 shares (grant or award)
- 4 Grant or award Director acquired 17,000 shares (grant or award)
- 4 Grant or award Director acquired 34,000 shares (grant or award)
- 4 Grant or award Director acquired 17,000 shares (grant or award)
- 4 Planned sale Director sold 52,855 shares at $18.27 ($965,402)
- 4 Planned sale Director sold 83,000 shares at an average $20.46 ($1,697,810)
- 4 Planned sale Director sold 52,855 shares at $20.40 ($1,078,068)
Page 3 of 13 · 259 filings